Propofol Versus Midazolam for Lower Gastrointestinal Endoscopy

Effect of Use of Propofol Versus Use of Midazolam as Sedative Agent in Patients With Liver Cirrhosis Presented for Lower Gastrointestinal Endoscopy, Randomised Controlled Trial

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03388151

Enrollment

100

Registered

2018-01-02

Start date

2016-04-01

Completion date

2022-12-11

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver

Brief summary

propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy

Detailed description

Effect of use of propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy, Randomised controlled trial.

Interventions

DRUGMidazolam

Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation

DRUGPropofol

Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

45 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Liver cirrhosis * presented to colonoscopy

Exclusion criteria

* Encephalopathy * Hypersensitivity * Coagulopathy

Design outcomes

Primary

Measure	Time frame	Description
Number of patients adequately sedated	6 months	The number of patients adequately sedated

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, MD

sheriefabdelsalam@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026